MUTZ 5 and MHH CALL4 were highly sensitive to AUY922 , with 50 to 1,000 fold superior potency compared with all the panel of JAK2 enzymatic inhibitors Fingolimod . AUY922 was also highly active against a panel of Ba/F3 lines dependent on CRLF2 and JAK2 . MHH CALL4 and MUTZ 5 cells have constitutive phosphorylation of STAT5 , JAK2 , JAK1 , ERK1/2 , and AKT , which is indicative of activation of these pathways. Using RNAi to individually deplete the JAK loved ones members, we confirmed that STAT5 phosphorylation in MHHCALL4 cells is dependent on JAK2 . Treatment with JAKinh 1 for 16 h decreased, but Fingolimod did not remove pSTAT5 and pERK1/2 in both lines. JAKinh 1 had small effect on pJAK1 and promoted increases in pAKT in MUTZ 5 and pJAK2 in MHH CALL4 , as observed in Ba/F3 JAK2 V617F cells treated with BVB808 .
Treatment with AUY922 for 16 h much more extensively Cilengitide decreased or eliminated phosphorylation of all of the targets. Total JAK2, and to a lesser extent JAK1, were also decreased in AUY922 treated cells . AUY922 promoted HSP70 up regulation in both lines , a known heat shock aspect 1 –mediated pharmacodynamic response to HSP90 inhibition. Similar effects on pJAK2, pStat5, pErk1/2, and pAkt were observed in Ba/F3 CRLF2/JAK2 R683S cells treated with all the HSP90 inhibitors HSP990 or PU H71 . Only MHH CALL4 has constitutive phosphorylation of STAT1, and this was eliminated by treatment with either JAKinh 1 or AUY922. The combination of AUY922+JAKinh 1 had small or no additional effect on target phosphorylation compared with AUY922 alone .
Furthermore, pairwise dose–response studies with isobologram analysis failed to identify synergistic effects from combination RNA polymerase treatment with AUY922+BVB808 in MHH CALL4 or MUTZ 5 cells . HSP90 inhibition elicits a transcriptional signature enriched for JAK2 and HSF1 signaling To evaluate the downstream programs resulting from JAK2 and HSP90 inhibition, we performed transcriptional profiling on MUTZ 5 and MHH CALL4 cells treated with vehicle , JAKinh 1, AUY922, or JAKinh 1+AUY922 . Unsupervised hierarchical clustering distinguished samples treated with AUY922 from those treated with JAKinh 1 or vehicle . We generated a heat map on the top/bottom differentially expressed genes for each condition 0. 25 and fold alter 2. 5; Table S3), which indicated that AUY922 treatment modulated the identical genes targeted by JAKinh 1 , but to a larger extent.
GSEA also demonstrated that STAT5A signatures were enriched upon treatment with JAKinh 1, AUY922, or JAKinh 1+AUY922 . To formally demonstrate that AUY922 targets the identical genes as JAKinh 1, we defined a JAK inhibitor signature from the top/bottom Cilengitide 250 most differentially expressed genes immediately after treatment with JAKinh 1. Using gene set enrichment analysis Fingolimod , the JAK inhibitor signature was highly enriched upon treatment with AUY922 . HSP90 acts at the posttranscriptional level, hence instant targets are certainly not directly assessed by transcriptional profiling. We applied the C3 database from the MsigDB compendium to carry out a transcription factor– binding internet site enrichment analysis on the most differentially expressed genes among JAKinh 1 and AUY922.
The best five ranked transcription factor–binding sites Cilengitide enriched within the AUY922 treated group were all heat shock components , which are known to be transcriptionally responsive to HSP90 inhibition . GSEA revealed that an HSF1 signature was only enriched upon treatment with AUY922 or AUY922+JAKinh 1, but not with JAKinh 1 alone . HSP90 inhibition is efficient against human CRLF2 rearranged B ALL in vivo To extend our findings towards the in vivo treatment of human B ALL, we established main B ALL xenografts from CRLF2 rearranged, patient derived bone marrow samples in NOD. Cg Prkdcscid Il2rgtm1Wjl/SzJ mice. Patient sample 412 harbors a CRLF2/IGH translocation plus a JAK2 R683S mutation. Patient sample 537 harbors a P2RY8 CRLF2 rearrangement and lacks a somatic mutation within the known components of CRLF2 signaling, based on transcriptome and exome sequencing .
To stringently assay established disease in vivo, we sacrificed sentinel animals weekly immediately after transplantation to assess engraftment. When bone marrow Fingolimod leukemia burden exceeded 30% , we initiated treatment with 50 mg/kg BVB808 twice every day by oral gavage, Cilengitide 50 mg/kg AUY922 thrice weekly i. v. , BVB808+AUY922, or vehicle. The dose of BVB808 was selected based on the demonstrated activity at this dose in Jak2 V617F–driven MPNs and earlier studies that demonstrated weight loss at greater doses . Right after 5 d of treatment, we sacrificed animals to assess pharmacodynamic endpoints. Spleens from mice treated with vehicle or BVB808 had nearly total effacement by B ALL, whereas AUY922 or BVB808+AUY922 treatment resulted in visible islands of hematopoiesis . Based on immunohistochemistry, mice receiving AUY922 or BVB808+AUY922 , but not BVB808 or vehicle, had nearly total loss of pSTAT5 and up regulation of HSP70 . Immunoblotting of spleens from treated mice demonstrated equivalent findings to those observe
Showing posts with label Fingolimod HSP90 Inhibitor Cilengitide FK866. Show all posts
Showing posts with label Fingolimod HSP90 Inhibitor Cilengitide FK866. Show all posts